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                                                    AIM of the study 
                                                   
 
The aim of the study is to test whether perioperative  sodium bicarbonate infusion 
can attenuate post operative increase in serum creatinine in cardiac surgical 
patients.This is done by studying the  
      (i)   Proportion of patients developing acute renal dysfunction defined as 
postop increase in serum creatinine >25% of baseline within first 5 postop days. 
(ii)  Proportion of patients developing blood urea >25% of baseline within 
first 5 days 
(iii)  Proportion of patients developing complications like alkalosis, 
hypokalemia and hypernatremia 
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                                                        INTRODUCTION 
 
 
 
        Acute renal dysfunction is a common and serious postoperative complication of 
cardiopulmonary bypass and may affect 25% to 50% of patients.(1-4) Acute renal failure 
is related to preoperative renal function as well as to the presence of coexisting disease. 
Cardiopulmonary bypass also may affect renal function adversely because the 
unphysiologic state of nonpulsatile flow may upset the normal autoregulatory 
mechanisms of renal blood flow. Acute renal dysfunction also carries significant costs.(5) 
and is independently associated with increased morbidity and  an increase in 
mortality.(6,7) 
                                            Urine acidity may enhance the generation and toxicity of 
reactive oxygen species induced by cardiopulmonary bypass. Activation of compliment 
during cardiac surgery may also participate in renal injury. Urine alkalinisation  may 
protect from renal injury induced by oxidant substances, iron mediated free radical 
pathways ,complement activation and tubular hemoglobin cast formation . 
                                       Accordingly we want to study whether  urine alkalinisation might 
protect kidney functions in patients at increased risk of renal dysfunction undergoing 
cardiopulmonary bypass by sodium bicarbonate infusion . 
                                       This study is a randomized controlled trial to see if sodium 
bicarbonate infusion is helpful in preventing increase in serum creatinine after 
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cardiopulmonary bypass. A group of 100 patients at increased risk of post operative renal 
dysfunction are randomized to either 24 hours of iv infusion of sodium bicarbonate or 
sodium chloride and serial  serum creatinine values to be taken for five consecutive days. 
                                   The primary outcome is the proportion of patients developing acute 
renal dysfunction defined as postoperative increase in plasma creatinine >25% of the 
baseline within the first five post operative days. 
                                        We also looked for increase in plasma urea levels >25%  of 
baseline within the first five days .Also for side effects of sodium bicarbonate infusion 
like hypernatremia,  hypokalemia, and metabolic alkalosis . 
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      METHODOLOGY 
 
 
Design overview: This study was a double blind, single centre, randomized 
controlled trial. The human research ethics committee, CMC  Vellore 
approved this study. Written informed consent was obtained from each 
patient. 
Setting and participant: Patients were identified in the hospital wards. We 
enrolled patients  at increased risk of postoperative acute renal dysfunction 
who were scheduled for elective cardiac surgery necessitating the use of 
cardiopulmonary bypass. 
All surgical approaches were by median sternotomy. The cardiopulmonary 
bypass circuit consisted of a roller pump, tubing, a membrane oxygenator 
and an arterial filter . The pump priming solution consisted of 700 ml of 
Ringer lactate, 500 ml of Haesteril with 50 ml of 20% Mannitol.  
Perioperative bypass management targeted a cardiac output of >2.5 l/min/m2     
and a mean arterial blood pressure of 40-60 mm hg .  The use of 
intraoperative fluid management was left to the discretion of  the 
anaesthetist. Analgesia was achieved with opioids like fentanyl and 
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morphine with avoidance of nonsteroidal anti-inflammatory drugs. Urine 
output was maintained at >0.5 ml/kg/hr. 
 
 
Intervention and Comparator agent:  This study deals with comparison of 
sodium bicarbonate  and sodium chloride infusion to prevent the renal 
dysfunction associated with cardiopulmonary bypass .Anaesthesia practice 
was not changed or modified for the purpose of the study and followed the 
same standard protocols. Patients were randomized and one group received 
8.4% sodium bicarbonate 0.5 meq/kg/hr  for 1 hour followed by 0.15 
meq/kg/hr infusion for 23 hours. The control group received 0.9% normal 
saline same volume and infused at the same rate. 
Key inclusion /Exclusion Criteria: Cardiac surgical patients in whom the 
use of cardio pulmonary bypass was planned and having one/more of the 
following risk factors for postoperative acute kidney injury 
Inclusion Criteria(any one or more of the following factors) : (i) 
age >60 yrs 
                            (ii) preexisting renal impairment ( preop serum 
creatinine >1.3 mg%) 
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                         (iii) NYHA class 3/4 or impaired LVF 
(LVEF<=45%) 
                        (iv)valvular surgery or concomitant valvular and 
coronary artery bypass graft surgery 
                       (v)redo cardiac surgery                        
                       (vi)type 2 Diabetes Mellitus 
Exclusion Criteria: 
(i) ESRD ( plasma creatinine >3.4 mg/dl ) 
(ii) Emergency cardiac surgery 
(iii) Planned off pump cardiac surgery 
(iv) Known blood borne infectious disease 
(v) Chronic inflammatory disease on immunosuppression 
Method of randomization: Randomisation codes were generated using 
block randomization method with size of 2, 4 and 6. 
Method of allocation concealment: The sequence was generated by the 
statistician and the allocation codes were serially numbered and  sealed in 
opaque envelopes which were handed over to the anaesthesia technician just 
before the surgery. He loaded the drugs accordingly .  
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Blinding and masking: Both participants and the investigators were blinded 
Primary outcome:  Proportion of patients developing acute renal 
dysfunction defined as postop increase in serum creatinine >25% of baseline 
within first 5 postop days. 
Secondary Outcomes : (a) Blood urea >25% of baseline within first 5 days 
                                             Complications: (b) Hypernatremia >150 meq/l 
                                                                      (c)alkalosis ph >7.5 
                                                                      (d)potassium <3.5 meq/l 
Target sample size and rationale: 100with 50 in each limb  
Sample size calculation:was calculated based on the formula n=(4pq)/d2  where 
 
P, the expected prevelance 
q=100-p 
and d, the precision of study  
According to the study Sodium bicarbonate to prevent increases in serum creatinine after 
cardiac surgery : A pilot double-blind ,randomized controlled trial, Critical care Med 
2009 Vol 37, No .1, a similar study was done in 100 patients with 50 patients receiving 
sodium bicarbonate  and the other receiving sodium chloride infusion. 
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1. Aute renal dysfunction in group 1 = 16/50  (p1= 32%) 
2. Acute renal dysfunction in group 2 = 26/50  (p2 = 52%) 
P =P1 +P2 
        2 
P=42  , Q=58 (1 –P) 
Expected difference between group 1 and 2  taken as 20% 
Level of significance = 5%     Zα = 1.96 
Power of the study =80%      Zβ = 1.282 
 
Sample size formula n = (Zα + Zβ)²×P×Q 
                                                 d²                                             
      
 Hence n = 90  in each limb .However due to lack of time only 100 patients were enrolled 
in the study . 
Phase of trial:Phase 3 
Estimated duration of trial: 6 months 
Statistical Analyses:  
Data entry was done using Microsoft excel and analysis was done using SPSS 
(Statistical Package for the Social Sciences) software package version 16 . 
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Statistical methods used for primary outcome:    (i) Descriptive statistics like mean 
and standard deviation were used for all study variables  (ii)comparison of 
outcomes by Two sample proportion test (iii)odd’s ratio with 95% confidence 
interval also were calculated.    Continuous variables were compared using T –test .      
The study design and methods were approved by the Fluid Research Committee, 
Christian Medical College ,Vellore . 
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                                      REVIEW OF LITERATURE 
 
 
Discussed under the following headings: 
 
1. CARDIOPULMONARY BYPASS 
       -USES 
       -SURGICAL PROCEDURES 
       -DESIGN  
       -COMPLICATIONS - RENAL  
           CAUSES OF RENAL FAILURE WITH CPB 
2. RENAL FAILURE 
        -RIFLE SCORE 
        -ACUTE KIDNEY INJURY 
        -PATHOPHYSIOLOGY 
3. SODIUM BICARBONATE 
4. CONTRAST INDUCED NEPHROPATHY 
5. STRATEGIES TO PREVENT RENAL FAILURE 
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CARDIOPULMONARY BYPASS 
 
 
Cardiopulmonary bypass (CPB) is a technique that temporarily takes over the 
function of the heart and lungs during surgery maintaining  the circulation of 
blood  and the oxygen content of the body .The CPB pump itself is often 
referred to as heart –lung machine . Cardiac surgery with cardiopulmonary 
bypass  is one of the common major surgical procedures in the world with more 
than one million surgeries per year.(8)  
USES OF CARDIOPULMONARY BYPASS 
Cardiopulmonary bypass is commonly used in heart surgery because of the 
difficulty of operating on the beating heart. Operations requiring the opening of the 
chambers of the heart require the use of CPB to support the circulation during that 
period.CPB can be used for the induction of total body hypothermia, a state in 
which the body can be maintained for up to 45 minutes without perfusion . . 
CPB mechanically circulates and oxygenates blood for the body while bypassing 
the heart and lungs. It uses a heart-lung machine to maintain perfusion to other 
body organs and tissues while the surgeon works in a bloodless surgical field. The 
surgeon places a cannula in right atrium, vena cava, or femoral vein to withdraw 
blood from the body. The cannula is connected to tubing filled with a priming 
solution. Venous blood that is removed from the body by the cannula is filtered, 
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cooled or warmed, oxygenated, and then returned to the body. The cannula used to 
return oxygenated blood is usually inserted in the ascending aorta, but it may be 
inserted in the femoral artery. The patient is administered heparin to prevent 
clotting, and protamine sulphate is given after to reverse effects of heparin. During 
the procedure, hypothermia is maintained; body temperature is usually kept at 28ºC 
to 32ºC (82.4-89.6ºF). The blood is cooled during CPB and returned to the body. 
The cooled blood slows the body’s basal metabolic rate, decreasing its demand for 
oxygen. Cooled blood usually has a higher viscosity, but the crystalloid solution 
used to prime the bypass tubing dilutes the blood. 
SURGICAL PROCEDURES IN WHICH CPB IS USED 
1. Coronary artery bypass surgery  
2. Cardiac valve repair and/or replacement (aortic valve, mitral valve,  
tricuspid valve, pulmonary valve) 
3. Repair of large septal defects (atrial septal defect, ventricular septal 
 defect, atrioventricular septal defect) 
4. Repair and/or palliation of congenital heart defects (Tetralogy of  
Fallot, transposition of the great vessels) 
5. Transplantation (heart transplantation, lung transplantation, heart- 
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lung transplantation) 
6. Repair of some large aneurysms (aortic aneurysms, cerebral aneurysms) 
7. Pulmonary thromboendarterectomy 
8. Pulmonary thrombectomy 
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DESIGN OF CPB CIRCUIT  
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The CPB machine has five basic components: 
(i) Reservoir : The reservoir of the CPB machine receives blood from the patient 
via one or two venous cannulas in the right atrium or the superior and inferior vena 
cava. Blood flows to the reservoir by gravity drainage. Because venous pressure is 
normally low, the driving force is directly proportional to the difference  in height  
between the patient  and the reservoir  but inversely  proportional to the resistance  
of the cannulas and tubing. 
(ii) Oxygenator: Blood is drained by gravity from the bottom of the venous 
reservoir into the oxygenator, which contains a blood – gas interface that allows 
blood to equilibrate with the gas mixture 
(iii) Heat exchanger:  Blood from the oxygenator enters the heat exchanger. The 
blood is then either cooled or warmed, depending on the temperature of the water 
flowing through the exchanger. Because gas solubility decreases as blood 
temperature rises, a filter is built into the unit to catch any bubbles that may form 
during rewarming. 
(iv) Main pump:  
(a) Roller pump: Roller pumps produce flow by compressing large bore tubing in 
the main pumping chamber as the heads turn. Subtotal occlusion of  the tubing 
prevents excessive  red cell trauma. The constant speed of the rollers pump blood 
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regardless of the resistance encountered and produces a continuous non pulsatile 
flow. 
(b) Centrifugal pumps: consist of a series of cones in a plastic housing .As the 
cones spin, the centrifugal forces created propel the blood from the centrally 
located inlet to the periphery. Because these pumps are nonocclusive, they are less 
traumatic to blood  than roller pumps 
(c) Pulsatile flow:  is possible with some roller pumps. Pulsatile flow improves 
tissue perfusion, enhances oxygen extraction, attenuates the release of stress 
hormones, and results in lower systemic vascular resistance. 
(v)Arterial Filter:  is used to prevent particulate matter which enters the CPB 
circuit  from causing systemic embolism. 
                 Other components are Cardiotomy suction, Left ventricular vent, 
cardioplegia pump and ultrafilter. (9) 
COMPLICATIONS OF CPB 
   CPB is a highly unphysiologic experience that triggers an explosion of 
adverse events affecting various systems such as cardiovascular, pulmonary, 
haematologic, renal and neurologic systems.  
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RENAL COMPLICATIONS 
 
 
Acute renal dysfunction is a common and serious postoperative complication of 
cardiopulmonary bypass and may affect 25% to 50% of patients.(1-4) Acute 
renal failure is related to preoperative renal function as well as to the presence of 
coexisting disease. CPB also may affect renal function adversely because the 
unphysiologic state of nonpulsatile flow may upset the normal autoregulatory 
mechanisms of renal blood flow.  
Acute renal dysfunction carries significant costs.(5) and is independently 
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associated with increased morbidity and  an increase in mortality.(6,7) In a 
prospective study done by Giorgio Zanardo,  in Italy, A total of 775 consecutive 
patients who survived the first 24 hours after cardiac operation were studied to 
assess the prevalence, mortality rate, and main risk factors for development of 
new acute renal failure. Normal renal function before operation (serum creatinine 
level less than 1.5 mg/dl) was registered in 734 (94.7%) patients. Of these, 111 
(15.1%) showed a postoperative renal complication including 84 (11.4%) 
classified as renal dysfunction (serum creatinine level between 1.5 and 2.5 
mg/dl) and 27 (3.7%) as acute renal failure (serum creatinine level higher than 
2.5 mg/dl). The mortality rate was 0.8% in normal patients, 9.5% in patients with 
renal dysfunction, and 44.4% when acute renal failure developed. The renal 
impairment proved to be an independent predictor of mortality . Multivariate 
analysis identified the following variables as independent risk factors for 
postoperative renal impairment: use of intraaortic balloon pump ( p < 0.0001), 
need for deep hypothermic circulatory arrest ( p < 0.005), low-output syndrome ( 
p < 0.005), advanced age ( p < 0.005), need for emergency operation ( p < 
0.025), and low urinary output during cardiopulmonary bypass ( p < 0.05). The 
41 patients (5.3%) with preoperative renal failure showed a significantly higher 
morbidity and mortality rate than those without renal complications before 
operation. It was concluded that in patients undergoing cardiac operation without 
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preexisting renal dysfunction the likelihood of severe renal complications is 
reasonably low (7) 
RENAL FAILURE 
 
 Acute  renal failure (ARF) is characterized by a rapid decline in  
glomerular filtration rate (GFR) over hours to days. Retention of nitrogenous waste 
products, oliguria (urine output< 400 ml/d) contributing to extracllular fluid 
overload), and electrolyte and acid base abnormalities are frequent  clinical 
features. ARF is divided into three major categories (i) pre renal ARF-diseases that 
cause renal hypoperfusion  (ii) intrinsic ARF –diseases that directly involve the  
renal parenchyma  (iii) postrenal ARF – diseases associated with  
urinary tract obstruction(10).  
 
 
In recent years the term acute renal failure has been replaced by Acute Kidney 
Injury(11) to define a more dynamic process of renal dysfunction  extending across 
initiation, maintenance and recovery phases, each of which may be of variable 
duration and severity.  
 
Another diagnostic classification scheme was developed by the Acute Dialysis Quality 
Improvement Initiative (ADQI)(3) Renal dysfunction is defined in terms of either a rise in 
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creatinine or a reduction in urine output, the more severe of the two criteria being 
selected. 
 
Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification 
 
 
Class Glomerular filtration rate 
criteria 
Urine output criteria 
Risk Serum creatinine × 1.5 < 0.5 ml/kg/hour × 6 hours 
Injury Serum creatinine × 2 < 0.5 ml/kg/hour × 12 
hours 
Failure Serum creatinine × 3, or 
serum creatinine ≥ 4 mg/dl 
with an acute rise > 0.5 
mg/dl 
< 0.3 ml/kg/hour × 24 
hours, or anuria × 12 hours
Loss Persistent acute renal 
failure = complete loss of 
kidney function > 4 weeks 
 
End-stage kidney disease  
End-stage kidney disease > 
3 months 
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Diagnostic criteria for acute kidney injury  
Emerging evidence suggests that even minor changes in serum creatinine are 
associated with increased in-patient mortality. ARF has been the focus of extensive 
clinical and basic research efforts over the last decades. During the last five years, 
several groups have recognized these limitations and have worked to identify the 
knowledge gaps and define the necessary steps to correct these deficiencies. These 
efforts have included consensus conferences and publications from the Acute 
Dialysis Quality Initiative (ADQI) group the American Society of Nephrology 
(ASN) ARF Advisory group the International Society of Nephrology (ISN), and 
the National Kidney Foundation (NKF) and KDIGO (Kidney Disease: Improving 
Global Outcomes) groups . Recognizing that future clinical and translational 
research in ARF will require multidisciplinary collaborative networks, the ADQI 
group and representatives from three nephrology societies (ASN, ISN, and NKF) 
and the European Society of Intensive Care Medicine met in Vicenza, Italy, in 
September 2004. They proposed the term acute kidney injury (AKI) to reflect the 
entire spectrum of ARF . 
Diagnostic criteria for acute kidney injury 
An abrupt (within 48 hours) reduction in kidney function currently defined as an 
absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 
 28
μmol/l), a percentage increase in serum creatinine of more than or equal to 50% 
(1.5-fold from baseline), or a reduction in urine output (documented oliguria of 
less than 0.5 ml/kg per hour for more than six hours). 
 
Classification/staging system for acute kidney injury   
 
 
Stage Serum creatinine criteria Urine output criteria 
1 Increase in serum creatinine of more than or 
equal to 0.3 mg/dl (≥ 26.4 μmol/l) or 
increase to more than or equal to 150% to 
200% (1.5- to 2-fold) from baseline 
Less than 0.5 ml/kg per 
hour for more than 6 hours
2 Increase in serum creatinine to more than 
200% to 300% (> 2- to 3-fold) from 
baseline 
Less than 0.5 ml/kg per 
hour for more than 12 
hours 
3  Increase in serum creatinine to more than 
300% (> 3-fold) from baseline (or serum 
creatinine of more than or equal to 4.0 
mg/dl [≥ 354 μmol/l] with an acute increase 
of at least 0.5 mg/dl [44 μmol/l]) 
Less than 0.3 ml/kg per 
hour for 24 hours or anuria 
for 12 hours 
 
Modified from RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney 
disease)criteria  .The staging system proposed is a highly sensitive interim staging 
system and is based on recent data indicating that a small change in serum 
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creatinine  influences outcome. Only one criterion (creatinine or urine output) has 
to be fulfilled to qualify for a stage. 200% to 300% increase = 2- to 3-fold increase 
.Given wide variation in indications and timing of initiation of renal replacement 
therapy (RRT), individuals who receive RRT are considered to have met the 
criteria for stage 3 irrespective of the stage they are in at the time of  
RRT.(12) 
 
PATHOPHYSIOLOGY OF RENAL FAILURE 
 
The effect of renal injury, whether from ischemia or from other causes , is a 
profound decrease in the GFR. This large decrease in filtration capacity of the 
kidney often occurs in the absence of overwhelmingly evident damage  to the 
kidney as seen on light microscopy.There are atleast three major classic proposed 
mechanisms for the fall in GFR : 
 
(i)  The first mechanism is a drop in the filtration pressure in the glomerulus.      
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(ii)  The second mechanism is tubular back leakage 
(iii) The third mechanism – Tubular Obstruction       
 
.
 31
 
                           
INFLAMMATION: 
Inflammation plays a central role in AKI. From initiation to extension through 
repair, inflammatory cells and soluble mediators are likely major determinants of 
the outcome from ARF.  
MICROVASCULAR  INFLAMMATION 
The proximal events leading to damage of renal tubular epithelial cells likely start 
in the microvasculature. The kidney receives 20% to 25% of cardiac output, and 
most of that blood flow is directed to the renal cortex. Postglomerular vessels, 
branching from efferent arterioles, eventually become the vessels of the vasa recta. 
The low flow state in the vasa recta is a critical aspect of the counter current 
multiplier, allowing for appropriate trafficking of water and solutes. However the 
low flow state leaves the medulla relatively hypoxic when compared with other 
regions of the kidney.The partial pressure of oxygen in the outer medulla is only 10 
to 20 mm Hg.Hence very slight decreases in the blood flow and oxygen delivery 
 32
can lead to anoxic damage. Anoxic injury to local cells, including vascular smooth 
muscle cells and endothelial cells, leads to depletion of  cellular energy stores and 
resultant disruption of  their actin cytoskeleton. The cellular deformities and 
hypoxia in and around the microvasculature leads to endothelial – erythrocyte 
interactions and promote sludging of RBCs. Peritubular capillaries  also take 
longer to recover nomal blood flow when compared with other intrarenal vessels.  
The combination of hypoxic injury, changes in endothelial cell morphology, and 
heightened interactions between RBC and endothelium leads to the extension of 
the initial renal injury. 
Leukocytes:  Early inflammation is classically characterized by margination of 
neutrophils to vascular endothelium. After the margination , firm adhesion occurs 
by the interactions of integrins with intercellular adhesion molecule-1. 
APOPTOSIS: 
Apoptosis plays a major role in the pathophysiology of ARF . IN apoptosis, the  
cell nucleus and cytoplasm condense and then split off  into smaller apoptotic 
bodies. Cytoplasmic organelles, including the mitochondria,  are often intact and 
are phagocytized by macrophages or other cells, which leads to spillage of cellular 
contents to cause inflammation. 
The signs of apoptosis in the kidney, initially heralded by DNA fragmentation in 
the cells of the thick ascending limb, can be seen within fifteen minutes of a 
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hypoxic insult in the kidney. A second peak in the amount of apoptosis in renal 
tissue occurs days to weeks after the initial insult 
THE ENDOTHELIAL CELL 
The endothelial cell plays an important role in the development of  ARF. When an 
initial insult damages the endothelium of the renal vessels, the result is an 
endothelial bed that is ineffective in regulating local blood flow and cell migration 
into tissues, and preventing coagulation. This vascular dysregulation, as 
perpetuated by dysfunctional endothelial cells, leads to continued ischemic injury 
following the initial insult, the extension phase of AKI.(13)      
 
 
SODIUM  BICARBONATE 
Sodium bicarbonate or sodium hydrogen carbonate is the chemical compound with 
the formula NaHCO3. Sodium bicarbonate is a white solid that is crystalline but 
often appears as a fine powder. It has a slightly salty, alkaline taste resembling that 
of washing soda(sodium carbonate).  The natural mineral form, nahcolite, is found 
in dissolved form in bile, where it serves to neutralize the acidity of the 
hydrochloric acid produced by the stomach, and is excreted into the duodenum of 
the small intestine via the bile duct.  
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History 
The ancient Egyptians used natural deposits of natron, a mixture consisting mostly 
of sodium carbonate decahydrate and sodium bicarbonate. The natron was used as 
a cleansing agent like soap.In 1791, a French chemist, Nicolas Leblanc , produced 
sodium carbonate, also known as soda ash . In 1846 two New York bakers, John 
Dwight and Austin Church, established the first factory to develop baking soda 
from sodium carbonate and carbon dioxide .Sodium bicarbonate is an amphoteric 
compound. Aqueous solutions are mildly alkaline due to the formation of carbonic 
acid and hydroxide ion: 
HCO−3 + H2O → H2CO3 + OH− 
Sodium bicarbonate can be used as a wash to remove any acidic impurities from a 
"crude" liquid, producing a purer sample. Reaction of sodium bicarbonate and an 
acid to give a salt and carbonic acid, which readily decomposes to carbon dioxide 
and water: 
NaHCO3 + HCl → NaCl + H2CO3 
H2CO3 → H2O + CO2(g) 
NaHCO3 + CH3COOH → CH3COONa + H2O + CO2(g) 
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Sodium bicarbonate reacts with bases such as sodium hydroxide to form 
carbonates 
Medical uses 
Sodium bicarbonate is used as an antacid taken orally to treat acid peptic disease. It 
may also be used in an oral form to treat chronic forms of metabolic acidosis such 
as chronic renal failure and renal tubular acidosis . Metabolic acidosis is usually 
not treated unless serum bicarbonate concentration falls below15 mmol/L or 
arterial pH falls below 7.2 .More severe acidosis is corrected by oral or intravenous 
sodium bicarbonate .Initial rates of replacement are guided by estimates of 
bicarbonate deficit  and adjusted thereafter  according to serum levels. 
 
Patients should be monitored for complications of sodium bicarbonate  
administration such as hypervolemia, hypokalemia.Sodium bicarbonate may also 
be useful for  forced alkaline diuresis in the treatment of  acute barbiturate 
poisoning , aspirin overdosage and uric acid renal stones.(14)It is used as well for 
treatment of hyperkalemia. 50-100 ml of 8.4% sodium bicarbonate will shift 
potassium into the cells reducing the serum levels of the same .Sodium bicarbonate 
has also been used in the treatment of tricyclic antidepressants overdose.  It can 
also be applied topically as a paste, with three parts baking soda to one part water, 
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to relieve insect bites .Sodium bicarbonate is also used as an ingredient in some 
mouthwashes. It works as a mechanical cleanser on the teeth and gums, neutralizes 
the production of acid in the mouth and also as an antiseptic to help prevent 
infections occurring. 
Medical preparation: Sodium bicarbonate is available as two preparations . 
(i) 8.4%  NaHCO3  which has 1437 mmol/L of Na , 1437 mmol/L  of HCO3,             
2874 mOsm/L .pH is 8.3 . 8.4% NaHCO3 contains 1 meq  of HCO3 per ml 
(ii)7.5%  NaHCO3  which has 1283 mmol/L of Na ,1283 mmol/L of HCO3 ,2566 
mOsm/L .pH 8.3 .7.5%  NaHCO3 contains 0.9 meq of HCO3 per ml . 
BASE EXCESS :  is the difference between the patients normal Buffer Base (BB) 
and  the actual BB .The base excess is a calculated value which estimates the 
metabolic component of an acid base  abnormality. It is an estimate of the amount  
of strong acid or base needed to correct the metabolic component of an acid base 
disorder .  
Correction =0.3 x body weight x Base excess 
Complete correction based on the above calculation is not clinically advisable as 
the body is in dynamic equilibrium and rapid correction can be deleterious 
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(paradoxical CSF acidosis, shift of the Hb dissociation curve causing tissue 
hypoxia) . 
CONTRAST  INDUCED NEPHROPATHY 
 A number of preventive measures have been proposed for contrast 
nephropathy.(15) It is clear that hydration is an effective preventive measure. Other 
measures that have been proposed include loop diuretics and mannitol, dopamine, 
fenoldopam, N acetyl cysteine, theophylline , and sodium bicarbonate.(16) Despite  
favourable experimental data, there is insufficient evidence to support the use of 
loop diuretics or mannitol to prevent radiocontrast nephropathy or any other cause 
of  ARF. Likewise ,despite its widespread use,dopamine has proved ineffective as 
a prophylactic agent. Fenoldopam, a dopamine a-1 specific agonist approved for 
use as a parenteral antihypertensive agent, has been tested in several clinical trials 
and does not appear to reduce the incidence of contrast nephropathy. Moreover, 
fenoldopam is associated with significant side effects, including systemic 
hypotension, and its use as an agent to prevent radiocontrast nephropathy should be 
discouraged. In contrast, several small  randomized control trials have suggested a 
clinical benefit to the use of N- acetyl cysteine (17), although meta-analyses have 
been inconclusive.(18). Acetylcysteine is the N-acetyl derivative of the amino 
acid L-cysteine,and is a precursor in the formation of the antioxidant glutathione in 
the body. Inhaled acetylcysteine is indicated for mucolytic ("mucus-dissolving") 
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therapy as an adjuvant in respiratory conditions with excessive and/or thick mucus 
production which include emphysema, bronchitis, tuberculosis, bronchiectasis, 
 amyloidosis, pneumonia, cystic fibrosis and COPD Chronic Obstructive 
Pulmonary Disease. It is also used post-operatively, as a diagnostic aid, and 
in tracheotomy care    .  Intravenous acetylcysteine is indicated for the treatment 
of paracetamol (acetaminophen) overdose However, aside from the potential 
hazards associated with a delay in radiographic imaging,N-acetyl cysteine appears 
to be safe, and its use in patients at high risk for radiocontrast nephropathy is 
reasonable, based on its low side effect .profile.(16) Larger RCTs will be required 
to show definitive benefit.  
However a few studies show that hydration  with sodium bicarbonate is better than 
hydration with sodium chloride for prophylaxis of contrast-induced renal 
failure.(19) 
A recent small prospective trial demonstrated that infusion of isotonic sodium 
bicarbonate was associated with a smaller increase in serum creatinine compared 
with isotonic saline, suggesting a benefit from alkalinization of the urine. (16) 
CAUSES FOR RENAL FAILURE WITH CPB: 
Various reasons stated are 
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(i)  Large fluid load typically administered with a crystalline CPB prime solution. 
(ii) The potassium usually administered as part of the cardioplegic solution .(20) 
(iii) Hypothermia is an independent factor for decrease in renal tubular function 
(iv) As there is decrease in global renal blood flow, there is redistribution of blood 
flow from cortex to outer medulla . 
(v) Intravascular hemolysis resulting in hemoglobinuria can cause acute tubular 
necrosis. It is not clear whether the mechanism is  precipitation of  pigment in the 
renal tubules with subsequent blockage of tubular flow/glomerular-tubular injuries 
caused by red cell stroma and other substances liberated from lysed RBCs .(21) 
Multiple other causes of cardiopulmonary bypass-associated acute 
renal dysfunction have been proposed, including (vi) ischemia-
reperfusion, (vii) generation of reactive oxygen species, (viii) 
hemolysis, and  (ix) activation of inflammatory pathways. (22-25)To 
date, no simple, safe, and effective intervention to prevent 
cardiopulmonary bypass-associated acute renal dysfunction in a broad 
patient population has been found .(26-28)  
Urinary acidity may enhance the generation and toxicity of reactive 
oxygen species induced by cardiopulmonary bypass. (25,29)Activation 
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of complement during cardiac surgery(30) may also participate in 
renal injury. Urinary alkalinization may protect from renal injury 
induced by oxidant substances, iron-mediated free radical pathways, 
complement activation, and tubular hemoglobin cast 
formation.(24,31,32) Of note, increasing urinary pH—in combination 
with N-acetylcysteine or without—has recently been reported to 
attenuate acute renal dysfunction in patients undergoing contrast-
media infusion. (19,33,34) 
STRATEGIES TO DECREASE THE INCIDENCE OF RENAL 
FAILURE. 
Previous double-blind randomized controlled trials attempting to prevent or 
attenuate acute renal dysfunction after cardiopulmonary bypass targeting 
oxidative stress, renal adenosine triphosphate consumption, and improvement 
of perioperative hemodynamic stability have been found to be 
ineffective.(26,28,35) , inconclusive or studied in specific cardiac surgical 
subpopulations(36). To date, no simple, safe, and effective intervention to 
prevent cardiopulmonary bypass-associated acute renal dysfunction in a broad 
patient population has been found (26-28). 
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However a study was  done by Dr Michael Haase  et al in Austin Hospital , 
Australia titled “Sodium bicarbonate to prevent increases in serum creatinine after 
cardiac surgery :A pilot double blinded , randomized controlled trial” (37). Here a 
cohort of 100 cardiac surgical patients at increased risk of postoperative acute renal 
dysfunction were selected and randomized to two groups .The study group (n=50) 
to receive 24 hours of intravenous infusion of sodium bicarbonate (4 mmol/kg) and 
the control group (n=50) to receive sodium chloride (4 mmol/kg) .The sodium 
bicarbonate or sodium chloride infusion were given at a dose of 0.5 mmol/kg body 
weight  (bolus) diluted in 250 ml of 5% dextrose water over 1 hour immediately 
after the induction of anaesthesia followed by continuous intravenous infusion of 
0.15 mmol/kg/hr (maintenance) diluted in 1000 ml of 5% dextrose over 23 hours 
(total dose of 4 mmol/kg over 24 hrs) . 
The primary outcome measure was the proportion of patients developing acute 
renal dysfunction defined as a postoperative increase in plasma creatinine 
concentration >25% of baseline within the first five postoperative days. Secondary 
outcomes included changes in plasma creatinine, plasma urea, urinary neutrophil 
gelatinase-associated lipocalin, and urinary neutrophil gelatinase-associated 
lipocalin/urinary creatinine ratio. Patients were well balanced for baseline 
characteristics. According to this study, sodium bicarbonate infusion increased 
plasma bicarbonate concentration , base excess,  plasma pH,  and urine pH and was 
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statistically significant. Fewer patients in the sodium bicarbonate group (16 of 50) 
developed a postoperative increase in serum creatinine compared with control (26 
of 50) with an odds ratio of 0.43 (p = 0.043). The increase in plasma creatinine, 
plasma urea, urinary neutrophil gelatinase-associated lipocalin, and urinary 
neutrophil gelatinase-associated lipocalin/urinary creatinine ratio was less in 
patients receiving sodium bicarbonate. There were no significant side effects. 
Hence the conclusion was that sodium bicarbonate loading and continuous infusion 
was associated with a lower incidence of acute renal dysfunction in cardiac 
surgical patients undergoing cardiopulmonary pass. This trial was based on the 
principle that the rise in serum creatinine after cardiopulmonary bypass might be 
due to a combination of tubular injury induced by reactive oxygen species, 
complement activation, and free hemoglobin release .  
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                                             RESULTS 
Between march 2010 and july 2010 we randomized 100 patients to receive 
intravenous sodium bicarbonate  A group(n=50) or sodium chloride  B group 
(n=50) .Two sample   t test with equal variances were used for statistical analysis . 
DEMOGRAPHIC DATA 
Table 1 : Age characteristics 
 
Table 2 : Age and sex characteristics 
 
    Sodium   
Bicarbonate 
         n=50 
       Sodium 
       Chloride 
          n=50 
 
   P value 
      
   Age 
>=6oyrs,mean 
 
    13(26%) 
 
       14(28%) 
 
     0.822 
 
   Males ,n 
 
     30(60%) 
 
       34(68%) 
 
     0.405 
 
    Sample (n)   Mean age( yrs)     Std error     Std dev 
Group A 50 49.6 2.147 15.18 
Group B 50 48.0 2.012 14.22 
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The mean age in both the study and control groups were comparable Group A 
being 49.6 and Group B being 48.0 years.There were no differences in both the 
groups in baseline characteristics like age and sex  as seen above in Table 1 and 2 
.Out of the 50 in sodium bicarbonate group 13 were >=60 years .Out of the 50 in 
the placebo group 14 were more than 60 years of age .Out of the 50 in A group 30 
were males and out of the 50 patients in B group 34 were females which was again 
not significant .There were no significant difference in the baseline characteristics 
like blood urea and serum creatinine .All patients had elective cardiac surgery 
either a CABG or a valve replacement . 
Table 3 :   Inclusion criteria 
  
Group A 
 
 Group B 
 
   Total 
 
 
P value 
     
   Age >=60 yrs, n (%) 
 
 13(26%) 
  
  14(28%) 
     
      27 
 
  0.822 
  
 Serum 
creatinine>=1.3 n% 
 
  6(12%) 
  
    5(10%) 
 
     11 
 
   0.749 
  
Left ventricular 
dysfunction, n (%) 
 
   6(12%) 
 
   7(14%) 
 
      13 
 
   0.766 
 
Valvular surgery, n 
(%) 
 
 26(52%) 
 
   19(38%) 
 
      45 
 
   0.218 
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CABG+ Valve 
surgery, n(%) 
 
      0 
 
     3(6%) 
 
       3 
 
   0.218 
 
Redo cardiac surgery, 
n(%) 
 
    3(6%) 
 
     4(8%) 
 
       7 
 
   0.218 
 
Diabetes Mellitus, 
n(%) 
  
  13(26%) 
 
    19(38%) 
 
       32 
 
   0.198 
 
As seen in the table above all the inclusion criterias were comparable . 
 
 
 
Table 4: Preoperative coomorbidities 
 
  
Group A
 
Group B
 
Total 
 
P value 
 
   Systemic hypertension, n(%)
 
17(34%)
 
15(30%)
 
   32 
 
 0.668 
  
   Hypercholestrolemia, n(%) 
 
14(28%)
 
18(36%)
 
   32 
 
  0.391 
 
   Atrial fibrillation, n(%) 
  
  4(8%) 
 
 5(10%) 
 
    9 
 
 0.727 
 
    Recent MI, n(%) 
 
 6(12%) 
 
 7(14%) 
 
   13 
 
 0.766 
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There is no statistically significant difference in preoperative comorbidities in both 
the study and control groups . 
Table 5 : Preoperative medications 
 
 Group A Group B Total P value 
ACE 
inhibitors 
15(30%) 20(40%) 35 0.295 
Β blockers 14(28%) 22(44%) 36 0.096 
Nitrates 13(26%) 19(38%) 32 0.198 
Antiplatelets 16(32%) 22(44%) 38 0.216 
 
All the preoperative medications are also comparable in both the groups. 
 
 
PREOPERATIVE MEASURES OF RENAL OUTCOME : 
 
Table 6 : Preoperative plasma urea 
 
 n mean Std error Std dev 
GROUP A 50 27.9 1.409 9.96 
GROUP B 50 25.62 1.146 8.108 
 
P value is 0.1062 
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Hence the plasma urea in both the study and control group were relatively the  
 
same.  
 
Table 7 : Preoperative serum creatinine 
 
 n mean Std error Std dev 
GROUP A  50 1.07 0.033 0.234 
GROUP B 50 1.092 0.037 0.265 
 
The baseline serum creatinine values are comparable with a p value of 0.669 . 
 
 
Fig 1 : Preoperative arrhythmias: 
 
4
46
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Group B
preop arrhythmias
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Group A Group B
 
  
The frequency of preoperative arrhythmias were almost same in both the study and 
control groups the p value being 0.727 
 48
INTRAOPERATIVE  FINDINGS : 
 
Table 8:  Cardiopulmonary bypass time  
 
 Mean time Std error Std dev 95% C I 
 
Group A 78.9 2.83 20 73.2-84.6 
Group B 79.2 2.28 16.2 74.5-83.7 
 
There is no significant difference between the study and control groups in terms of 
cardiopulmonary bypass time which is approximately about 79 minutes ..The p 
value is 0.9476 
Fig 2 : Types of surgeries 
.
cabg, 21
cabg, 24
valvular sx, 26
valvular sx, 19
redo sx, 3
redo sx, 4
cabg+valve sx, 3
0
5
10
15
20
25
30
TYPES OF SURGERIES
Group A 
Group B
Group A 21 26 3 0
Group B 24 19 4 3
cabg valvular sx redo sx cabg+valve sx
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The types of surgeries in both the study and control groups are comparable with a p value 
of 0.218 
 
 
INTRAOPERATIVE ARTERIAL BLOOD GAS: 
 
 
During the surgery three ABGs were done .First (A sample)  is a baseline Abg 
done immediately after intubation and before giving heparin or going on bypass 
.Second (B sample) was during bypass and third ABG ( sample)was after coming 
off  bypass . 
Fig 3: A SAMPLE  : SODIUM  
        
Group A
5, 10%
42, 
84%
3, 6%
<130
meq
130-
150meq
>150
meq
       
Group B
5, 10%
43, 
86%
2, 4%
<130
meq
130-
150meq
>150
meq
 
Even though Group A received more sodium as 8.4% NaHCO3 infusion than 
Group B,  there is no statistically significant difference between the two groups in 
terms of the serum sodium levels in A sample ,the p value being 1.000 . 
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 Fig 4: A SAMPLE - POTASSIUM 
         
Group A
10, 
20%
38, 
76%
2, 4% <3.5
meq
3.5-
5.5meq
>5.5
meq
  
Group B
8, 16%
41, 
82%
1, 2%
<3.5
meq
3.5-
5.5meq
>5.5
meq
 
One of the known side effects of sodium bicarbonate is hypokalemia . In our study 
out of the 50 patients who received sodium bicarbonate infusion10 developed 
hypokalemia compared to  8 out of 50 who received saline infusion which is not 
statistically significant with a p value of 0.716 . 
Fig 5: A  SAMPLE - PH 
Group A
43, 86%
7, 14% 7.3 -
7.5
>7.5
                  
Group B
40, 
80%
10, 
20% 7.3 -
7.5
>7.5
 
          
Contrary to what was expected , only 7 out of 50 patients of the study group 
developed ph >7.5 compared to 10 out of 50 patients in the control group .As such 
the results were not statistically significant .p value 0.424 . 
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Fig 6: A SAMPLE – PACO2 (mm Hg) 
Group A
20, 
40%
2, 4%
28, 
56%
<35 mm
35-45
mm
>45 mm
            
Group B
15, 
30%
29, 
58%
6, 12% <35
mm
35-45
mm
>45
mm
 
The infusion of sodium bicarbonate in  study patients did not cause a significant 
difference in the PACO2 levels compared to the control group .p value was 0.255 
 
Fig 7: A SAMPLE- BICARBONATE 
Group A
27, 54%
11, 22%
12, 
24%
<24
24-28
>28
          
Group B
13, 
26%
26, 
52%
11, 
22% <24
24-28
>28
 
P value is 0.971 .Comparing  Group A and Group B there is no statistically 
significant difference between the 2 groups in regards with raised or lowered 
bicarbonate levels before going on pump 
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Fig 8: A SAMPLE – BASE EXCESS 
 
Group A
43, 
86%
7, 14%
-5 to
+5
>+5
              
Group B
44, 
88%
6, 12%
-5 to
+5
>+5
 
None of the patients developed a base excess of <-5 . 7 out of 50 in study group 
developed base excess of   >5 and  6 out of 50 patients in the control group 
developed base excess of >5 . p value is 0.766 which is not statistically significant . 
B SAMPLE  : B sample is the arterial blood sample taken when the patient is on 
cardiopulmonary bypass . 
Fig 9:  B SAMPLE- SODIUM 
 
Group A
6, 12%
44, 
88%
<130
meq
130-
150meq
                
Group B
8, 16%
42, 
84%
<130
meq
130-
150me
q
 
None of the patients in both the study groups had serum sodium levels >150 meq.  
6 out of 50 patients in study group had serum sodium  <130 meq  whereas 8 out of 
50 patients in the control group developed serum sodium  <130 meq. There is no 
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statistically significant difference in both the groups when we compared the 
sodium levels .p value =0.564 
Fig 10: B SAMPLE - POTASSIUM 
 
Group A
1, 2%
33, 66%
6, 32%
<3.5
3.5-5.5
>5.5
              
Group B
0, 0%
30, 
60%
20, 
40%
<3.5
3.5-
5.5
>5.5
 
                
   Study group :Out of 50 patients 1 developed serum K+ <3.5 meq  ,16 had serum 
K+    >5.5 meq, and 33 had potassium in the normal range .  
Control group :20 patients developed serum K+ >5.5  and 30 had in the normal 
range.     The p value is 0.452 . Hence the serum potassium values in both the 
groups  are comparable with no significant difference. 
Fig 11:   B SAMPLE- PH 
GROUP A
0, 0%
47, 
94%
3, 6% <7.3
7.3-
7.5
>7.5
               
GROUP B
3, 6%
43, 
86%
4, 8% <7.3
7.3-
7.5
>7.5
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Study group :3 out of 50 had pH >7.5 .Rest had ph in the normal range .Control     
group :4 out of 50 had pH >7.5,3 had  pH  <7.3 and the remaining had normal pH 
P value is 0.190 .There is no statistically significant difference in both the groups 
with regards to the ph . 
Fig 12:  B SAMPLE : PACO2 (mm Hg) 
 
         
             
Study group :Out of 50 patients 5 had PACO2 >45 ,35 in the normal range and 10 
in the group with PACO2<35 mm Hg 
Control group :Out of 50 patients 5 had PACO2 >45,29 in the normal range and 16 
with PACO2 of <35 mmHg 
P value is 0.378 .Comparing  Group A and Group B there is no statistically 
significant difference between the 2 groups with regards to raised or lowered 
PACO2 levels after going on pump . 
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Fig 13:  B SAMPLE - BICARBONATE ( meq) 
 
GROUP A
<24 
meq
22%
>28 
meq
20%
24-
28meq
58%
<24
meq
24-
28meq
>28
meq
                   
GROUP B
<24 
meq
48%
>28 
meq
4%
24-
28meq
48%
<24
meq
24-
28me
q
>28
meq
 
              
 
Out of 50 patients in the control group 24 patients had bicarbonate levels <24 .Out 
of the 50 patients in the study group only 11 developed serum bicarbonate levels 
<24 with a p value of 0.005 which is statistically significant .Out of 50 in the 
control group only 2 developed serum bicarbonate levels > 28 and in the study 
group 10 out of 50 developed alkalosis which is again significant . 
 
Fig 14:  B SAMPLE -BASE EXCESS 
 
GROUP A
0, 0%
46, 
92%
4, 8%
<-5
-5 to
+5
>+5
              
GROUP B
47, 94%
0, 0% 3, 6%
<-5
-5 to
+5
>+5
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None of the patients in the study group developed base excess <-5and none in the 
control group developed base excess > +5 .However the base excesses values are 
comparable in both groups without any statistical significance p value = 0.039 
Fig 15:  C SAMPLE - SODIUM 
Group A
5, 10%
45, 
90%
<130
meq
130-
150meq
               
Group B
4, 8%
46, 
92%
<130
meq
130-
150meq
 
 
In both the study and the control groups none of the patients developed serum 
sodium >150 meq .Otherwise the serum sodium levels are comparable in both the 
groups with a p value of 0.727. 
 
Fig 16: C SAMPLE-POTASSIUM 
 
GROUP A
32%
66%
2%
<3.5
meq
3.5-
5.5meq
>5.5
meq
             
GROUP B
32%
2%
66%
<3.5
meq
3.5-
5.5me
q
>5.5
meq
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The potassium values are exactly same in both the study and control groups with a 
p value of 1.000 
Fig 17:  C SAMPLE - PH 
 
 
GROUP A
80%
18%2% <7.3
7.3-7.5
>7.5
                
GROUP B
26%
74%
0%
<7.3
7.3-7.5
>7.5
 
 
 
P value is0.228 .There is no statistically significant difference in both the groups in 
regards to the ph . 
 
Fig 18:  C SAMPLE -PACO2 
 
GROUP A
9, 18%
27, 
54%
14, 
28%   <35 
  35-45
  >45 
           
GROUP B
11, 
22%
30, 
60%
9, 18%
  <35 
  35-
45
  >45 
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P value is 0.486 .Comparing  Group A and Group B there is no statistically 
significant difference between the 2 groups with regards to raised or lowered 
PACO2 levels after coming off pump . 
 
Fig 19: C SAMPLE - BICARBONATE (HCO3) 
 
GROUP A
32, 
64%
2, 4%16, 
32%
<24
meq
24-
28meq
>28
meq
                 
GROUP B
46, 
92%
0, 0%4, 8% <24
meq
24-
28meq
>28
meq
 
 
Out of the 50 patients who received sodium bicarbonate infusion ,32 patients had 
bicarbonate value <24 meq compared to 46 patients out of the 50 patients who 
received sodium chloride infusion. This was statistically significant with a p value 
of 0.003 which means that sodium bicarbonate infusion can actually reduce the 
metabolic acidosis which can occur otherwise . 
Fig 20:  C SAMPLE - BASE EXCESS 
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GROUP A
8, 16%
42, 
84%
0, 0% <-5
-5 to
+5
>+5
             
GROUP B
1, 2%
32, 
64%
17, 
34% <-5
-5 to
+5
>+5
 
 
P value is 0.061 which means that there is no statistically significant difference 
between the two study groups in terms of base excess . 
 
MORTALITY: There were 2 deaths which occurred during the study .One was a 
50 yr old lady(study group)  who underwent a redo MVR who went into low 
cardiac output syndrome immediately post op . she was started on high inotropic 
support .Due to clots in the pericardium she was taken up for a reexploration . 
Postoperatively she went into acute renal failure not responding to diuretics .She 
received repetitive dialysis, eventually went into liver failure and expired after 10 
days . 
The second case was that of a 69 year old gentle man ( control group) who 
underwent a CABG .He developed worsening of renal functions postoperatively 
.He also had mesenteric ischemia .  Laporotomy was done after 6 days .There was 
further worsening of renal functions and eventually he died after 3 days  . 
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PRIMARY OUTCOME :   
 
 
 
Fig 21:Proportion of patients developing acute renal dysfunction defined as 
postoperative increase in serum creatinine >25% of baseline within first 5 postop 
days.
21
29
24
26
0
5
10
15
20
25
30
Group A Group B
>25% increase in Se creatinine
<25% increase in Se creatinine
 
 
The p value is 0.546 which means that there is no significant statistical difference 
between the study group and control group in terms of post operative increase in 
Serum creatinine >25% from the baseline within the first five postoperative days . 
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Fig 22: Proportion of patients developing acute renal dysfunction defined as post  
 
operative increase in se creatinine>50% from the baseline 
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43
14
36
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45
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>50% increase in Se creatinine
<50% increase in Se creatinine 
 
 
The p value is 0.086 which means that there is no significant statistical difference 
between the study group and control group in terms of post operative increase in 
Serum creatinine >50% from the baseline within the first five postoperative days . 
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Fig 23: Postoperative increase in serum creatinine >100% from the baseline 
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The p value is 0.461 which means that there is no significant statistical difference 
between the study group and control group in terms of post operative increase in 
Serum creatinine >100% from the baseline within the first five postoperative days . 
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Fig 24: Postoperative 25% increase in plasma urea from the baseline 
5
45
8
42
0
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10
15
20
25
30
35
40
45
Group A Group B
>25% increase in pl urea
<25% increase in pl urea
 
There is no statistical difference between the study group and control group in 
terms of increase in plasma urea from the baseline .The p value being 0.198 
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Fig 25: GRAPH SHOWING TREND OF SERUM CREATININE IN BOTH THE 
STUDY AND CONTROL GROUP 
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Fig 26: POSTOPERATIVE ARRHYTHMIAS 
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The incidence of post operative arrhythmias was same in both the study and 
control groups with p value of 1.000 
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                                             DISCUSSION 
 
We conducted a double-blind, randomized controlled clinical trial  from  march 
2010 to june 2010 in the Department of Anaesthesia CMC Vellore .The aim was to 
investigate whether sodium bicarbonate infusion with preoperative intravenous 
loading to achieve urinary alkalinization could attenuate the creatinine rise 
associated with cardiopulmonary bypass in cardiac surgical patients at increased 
risk. We randomized 100 patients to receive either sodium bicarbonate 
infusion(study group) or sodium chloride infusion (control group) .All patients 
were Indians most of them from West Bengal and the other group mainly from 
Tamilnadu . All  patients had elective cardiac surgery- either a CABG or a valve 
replacement .We enrolled patients with a variety of cardiac surgeries so that our 
results may have implications for a wide variety of cardiac cases .The internal 
validity of our results was strengthened by double blinding and central 
randomization . 
This study was conducted based on another study done by Dr Michael Haase et al 
in Austin Hospital , Australia titled “Sodium bicarbonate to prevent increases in 
serum creatinine after cardiac surgery :A pilot double blinded , randomized 
controlled trial” .Here a cohort of 100 cardiac surgical patients at increased risk of 
postoperative acute renal dysfunction were selected and randomized to two groups 
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.The study group (n=50) to receive 24 hours of intravenous infusion of sodium 
bicarbonate (4 mmol/kg) and the control group (n=50) to receive sodium chloride 
(4 mmol/kg) .The sodium bicarbonate or sodium chloride infusion were given at a 
dose of 0.5 mmol/kg body weight  (bolus) diluted in 250 ml of 5% dextrose water 
over 1 hour immediately after the induction of anaesthesia followed by continuous 
intravenous infusion of 0.15 mmol/kg/hr (maintenance) diluted in 1000 ml of 5% 
dextrose over 23 hours (total dose of 4 mmol/kg over 24 hrs) . 
The primary outcome measure was the proportion of patients developing acute 
renal dysfunction defined as a postoperative increase in plasma creatinine 
concentration >25% of baseline within the first five postoperative days. Secondary 
outcomes included changes in plasma creatinine, plasma urea, urinary neutrophil 
gelatinase-associated lipocalin, and urinary neutrophil gelatinase-associated 
lipocalin/urinary creatinine ratio. Patients were well balanced for baseline 
characteristics. According to this study, sodium bicarbonate infusion increased 
plasma bicarbonate concentration , base excess,  plasma pH,  and urine pH and was 
statistically significant. Fewer patients in the sodium bicarbonate group (16 of 50) 
developed a postoperative increase in serum creatinine compared with control (26 
of 50) with an odds ratio of 0.43 (p = 0.043). The increase in plasma creatinine, 
plasma urea, urinary neutrophil gelatinase-associated lipocalin, and urinary 
neutrophil gelatinase-associated lipocalin/urinary creatinine ratio was less in 
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patients receiving sodium bicarbonate. There were no significant side effects. 
Hence the conclusion was that sodium bicarbonate loading and continuous infusion 
was associated with a lower incidence of acute renal dysfunction in cardiac 
surgical patients undergoing cardiopulmonary pass. This trial was based on the 
principle that the rise in serum creatinine after cardiopulmonary bypass might be 
due to a combination of tubular injury induced by reactive oxygen species, 
complement activation, and free hemoglobin release .Hence the first study done 
was successful in establishing these facts . 
                    Similar to this study, we also measured  the proportion of patients 
developing acute renal dysfunction defined as postoperative increase in serum 
creatinine >25% of baseline within first 5 postoperative days (primary outcome). 
In the control group out of 50 patients 24 developed acute renal dysfunction and 
out of the study group only 21 out of 50 patients developed renal dysfunction 
.However these findings were not statistically significant (p value =0.546).Hence 
we concluded that sodium bicarbonate infusion did not cause any risk reduction for 
acute renal dysfunction in cardiac surgical patients . 
Also in previous RCTs, urine alkalinisation with sodium bicarbonate infusion for 
patients undergoing contrast media infusion (another condition where free oxygen 
radical generation is involved) has been found to attenuate acute kidney injury . 
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In our study, there was no significant difference between both the groups in 
baseline characteristics such as age ,sex ,baseline serum creatinine and plasma 
urea. We included patients who are at a high risk for renal dysfunction in this 
study which included age >60 yrs, preexisting renal impairment ( preop serum 
creatinine >1.3 mg%),NYHA class 3/4 or impaired LVF (LVEF<=45%) , 
valvular surgery or concomitant valvular and coronary artery bypass graft 
surgery, redo cardiac surgery, type 2 Diabetes Mellitus .All the inclusion 
criteria characteristics were also comparable . 
Preoperative comorbidities like systemic hypertension, hypercholesterolemia, atrial 
fibrillation and recent MI were also comparable in both the groups . Preoperative 
medications were also similar in both the groups . 
Intraoperatively, the cardiopulmonary bypass time was approximately 78 minutes in 
both the groups . 
RENAL OUTCOME 
As mentioned in the literature review ,the latest diagnostic criteria for acute kidney 
injury is classified into stage (i) increase in serum creatinine 1.5-2 times from baseline 
,stage (ii) increase in serum creatinine 2-2.5 times,stage (iii)increase in serum 
creatinine >3 fold. Accordingly we measured the primary outcome of acute renal 
dysfunction as postoperative increase in serum creatinine >25% of baseline within 
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first 5 postop days .Secondary outcomes measured included (a) post operative increase 
in serum creatinine>50% from the baseline (b) post operative increase in serum 
creatinine >100% from the baseline and (c)post operative increase in plasma urea 
>25% from the baseline .Although less number of patients from the study group 
developed acute renal dysfunction, the results were not statistically significant . 
OTHER OUTCOMES 
 During the surgery, 3 Arterial Blood Gas estimations were done .There was 
significant metabolic acidosis in patients in the control group compared to the study 
group in terms of serum bicarbonate. Hence we can infer that sodium bicarbonate was 
useful intraoperatively to decrease the incidence  of acidosis . 
SAFETY 
We checked for side effects of sodium bicarbonate infusion like hypernatremia, 
hypokalemia, any peri operative arrhythmias .None of the patients in the study group 
developed any of the above mentioned complications which was statistically 
significant . 
 
COMPARISON OF THE TWO STUDIES : 
Both the studies were done in a similar way but had contradicting results .Both the 
studies were similar in most  aspects except for the population group. The first study 
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mainly had a population from Australia .Our study involved a mixed Indian 
population . 
The first study measured other parameters like urinary neutrophil gelatinase-
associated lipocalin (NGAL) concentration and urinary NGAL/urinary creatinine ratio 
within the first 24 hours after commencement of cardiopulmonary bypass.(38) 
.Neutrophil gelatinase-associated lipocalin (NGAL) is expressed and secreted by 
immune cells, hepatocytes, and renal tubular cells in various pathologic states. NGAL 
acts as a growth and differentiation factor in multiple cell types, including developing 
and mature renal epithelia, and some of this activity is enhanced in the presence of 
siderophore:iron complexes. NGAL is massively upregulated after renal tubular injury 
and may participate in limiting kidney damage.(39, 40) Hence it is a very sensitive 
marker for acute kidney damage .However we could not use NGAL due to 
nonavailability and high costs of the same . 
Our interest in sodium bicarbonate to prevent renal dysfunction came up after 
reviewing a few other studies also . Merten et al in 2004 studied the effect of 
sodium bicarbonate infusion on contrast induced nephropathy.  A prospective, 
single-center, randomized trial conducted by them on 119 patients with stable 
serum creatinine levels of at least 1.1 mg/dL who were randomized to receive a 
154-mEq/L infusion of either sodium chloride (n = 59) or sodium bicarbonate (n = 
60) before and after iopamidol administration (370 mg iodine/mL). Serum 
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creatinine levels were measured at baseline and 1 and 2 days after contrast. 
Contrast-induced nephropathy was defined as an increase of 25% or more in serum 
creatinine within 2 days of contrast.  The primary end point of contrast-induced 
nephropathy occurred in 8 patients infused with sodium chloride but in only 1 of 
those receiving sodium bicarbonate;  Hydration  with sodium bicarbonate before 
contrast exposure is more effective than hydration with sodium chloride for 
prophylaxis of contrast-induced renal failure.(19) 
Wong et al studied the use of various therapies in contrast induced 
nephropathy(CIN).CIN is usually defined as an increase in serum creatinine of 44 
µmol litre−1 (0.5 mg dl−1) or a 25% increase from the baseline value 48 h after 
intravascular injection of contrast media. It is a common and potentially serious 
complication of the use of iodinated contrast media in patients at risk of acute renal 
injury .Impact of CIN on clinical outcomes has been evaluated most extensively in 
patients undergoing percutaneous coronary intervention where it is associated with 
increased mortality both in hospital and at 1 year after the intervention. This trial 
demonstrated that infusion of isotonic sodium bicarbonate was associated with a 
smaller increase in serum creatinine compared with isotonic saline, suggesting a 
benefit from alkalinization of the urine. (16). 
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However we found that sodium bicarbonate was not efficacious to prevent 
increases in serum creatinine after cardiac surgery . The only benefit of sodium 
bicarbonate infusion revealed in this study was that metabolic acidosis(incurred by 
CPB period) can be avoided or the incidence can be kept low. The other important 
finding in this study is that there is a significant40-50% incidence of high risk of 
patients developing renal dysfunction after CPB .The results of this study may 
have been  different if we had been more strict in the inclusion criteria and 
included only those patients with preexisting renal dysfunction as depicted by 
elevated serum creatinine .These findings need to be confirmed or refuted by 
further clinical investigations in other geographic and institutional settings . 
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                                                  LIMITATIONS 
 
1. The recommended target of sample size could not be achieved during the 
time period of the study .This could have influenced the outcomes of the 
study . 
2. The results of this study may have been  different if we had been more strict 
in the inclusion criteria and included only those patients with preexisting 
renal dysfunction as depicted by elevated serum creatinine 
3. We could not use highly sensitive markers of renal dysfunction like NGAL 
due to high costs involved and non availability. 
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                                            CONCLUSIONS 
1. There is a significant 40-50% incidence of patients developing acute 
renal dysfunction after cardiopulmonary bypass in the high risk group. 
2. Sodium bicarbonate infusion did not cause any decrease in incidence 
of renal dysfunction in cardiac surgical patients . 
3. Sodium bicarbonate infusion was useful intraoperatively to decrease 
the incidence of metabolic acidosis otherwise associated with 
cardiopulmonary bypass . 
4. None of the patients developed side effects like hypernatremia, 
hypokalemia, and perioperative arrhythmias which was statistically 
significant . 
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                                                  ANNEXURE  I 
 
 
                               PATIENT INFORMATION SHEET 
 
 
Patients who need to undergo a cardiac surgery often need to undergo 
cardiopulmonary bypass.This means that the heart and lung work will be taken 
care of  by a machine (heart lung machine)during the operation. However it’s been 
proved that patients on cardiopulmonary bypass have increased chance of kidney 
damage .This study is an attempt to see if  infusion of sodium bicarbonate for 24 
hours (low dose)can decrease the incidence of this complication.This is not a new 
drug. It is used very often during routine cardiac surgeries.During this surgery 
there is chance of body sodium and bicarbonate levels going up.But these are 
routinely monitored and treatment can be given promptly. 
                                    For this study you will be randomly chosen to get  a low 
dose of either sodium bicarbonate or normal saline infusion for 24 hours . Blood 
samples will be taken during  and after surgery to check sodium , potassium , acid 
base status and tests to know the kidney functions .These tests are routinely done 
after any cardiac surgery.  
                                         However volunteering for this study is optional and the 
care that you receive in this hospital will not be affected by your decision 
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                                            ANNEXURE  II 
 
 
 
                         INFORMED CONSENT 
 
I _________________________, Hosp no :______________________                      
have been explained in detail about the study  .I am willing to volunteer 
at my own free will and am aware that I can withdraw at any time 
without it affecting my medical care in this hospital. 
 
Doctor’s name: 
Signature:                                                             Signature of the patient  
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                                     ANNEXURE   III 
 
                            DATA  ENTRY    PROFORMA 
Serial no:           
                                                                                  Date: 
Name of the patient:  
                                                                  Name of the surgery: 
Hospital no:                                           Age:            Weight: 
   
INTAROPERATIVE VALUES: 
           A           B           C 
     Serum sodium    
Serum potassium    
                    ph    
 
 
POST OPERATIVE VALUES: 
Post op       Day 1      Day  2      Day 3     Day 4    Day 5 
Serum 
creatinine 
     
 
 
 
    Post op        Day  1           Day  2            Day 3 
          Blood urea    
     Serum sodium    
Serum potassium    
                          ph    
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